This is the first and only conference to focus on bioconjugation techniques from a holistic standpoint. Going beyond just ADCs, to look at the latest research and innovations across all
This is the first and only conference to focus on bioconjugation techniques from a holistic standpoint. Going beyond just ADCs, to look at the latest research and innovations across all topics within bioconjugates including ADCs, bispecific conjugations, nanoparticle conjugations and more.
Complete Brochure Now Available
» Download Today!
\’It was a pleasure presenting at the Bioconjugates conference in June 2014. The presentations and discussion were very stimulating and there was excellent new information.\’ – Philip Howard, Ph.D., Chief Scientific Officer, Spirogen, United Kingdom
By Attending You Will:
- Gain insights on novel payloads, new linkers and alternative binding modalities, and updates on the latest in ADC discovery and development
- Hear Seattle Genetics and Genentech present their strategies for overcoming CMC and regulatory challenges
- Learn from advances beyond ADCs, including bispecific conjugations, nanoparticle conjugations and more
\’Great variety of bioconjugation modalities. I\’m sure this sort of crosstalk will create new innovations.\’ – Roger Pak, Pfizer
Peter Senter, Ph.D.
Vice President, Chemistry
Paul J. Carter, Ph.D.
Staff Scientist and Senior Director, Antibody Engineering
Andreas Plückthun, Ph.D.
Director, Department of Biochemistry
University of Zurich, Switzerland
Vice President, Research; General Manager
Amgen Research GmbH, Germany
Jim Wells, Ph.D.
Professor and Chair, Pharmaceutical Chemistry
Mark Dennis, Ph.D.
Principal Scientist, Antibody Engineering
\’A great conference with all the experienced scientists involved in ADC therapeutics – \’one-and-only shop for ADCs\’ – great location too.\’ – Ananda Senevir, Agensys
may 18 (Monday) - 20 (Wednesday)
Parc 55 Hilton
San Francisco, California